Missed the webcast with Professor David Nutt, Founder of Drug Science and Tejinder Virk, President of Khiron Europe?

There was lots to learn about how the two organizations are working together on Project Twenty21, Europes first and largest medical cannabis registry.

With an eye on global expansion, Khiron became the exclusive Latin American company participating in Project Twenty 21.

Our primarily operations are in Latin America, with a market of 620 million people in  the region, where we are revenue generating, but we have also operations, revenues, and partnerships spanning 7 countries and 3 continents - North America, South America, and Europe. 

As Khiron shifts toward the sales-execution phase of its business plan, it is targeting markets it perceives as having the greatest near-term revenue potential and ROIC; these countries include Colombia, Brazil, Peru, the UK, and Germany, where sales have commenced or are expected.